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We  assessed  lineage  involvement  by  NUP98  translocations  in myelodysplastic  syndromes  (MDS),  acute
myeloid  leukaemia  (AML),  and  T-cell  acute  lymphoblastic  leukaemia  (T-ALL).  Single  cell  analysis  by
FICTION  (Fluorescence  Immunophenotype  and  Interphase  Cytogenetics  as  a Tool  for  Investigation  of
Neoplasms)  showed  that,  despite  diverse  partners,  i.e. NSD1,  DDX10,  RAP1GDS1,  and  LNP1,  NUP98  translo-eywords:
UP98 translocations
eukaemia
ineage afﬁliation
ingle cell analysis
cations  always  affected  a  CD34+/CD133+  hematopoietic  precursor.  Interestingly  the  abnormal  clone
included  myelomonocytes,  erythroid  cells,  B-  and  T- lymphocytes  in  MDS/AML  and  only  CD7+/CD3+  cells
in T-ALL.  The  NUP98-RAP1GDS1  affected  different  hematopoietic  lineages  in AML  and  T-ALL.  Additional
speciﬁc  genomic  events,  were  identiﬁed,  namely  FLT3  and  CEBPA  mutations  in  MDS/AML,  and  NOTCH1
mutations  and  MYB  duplication  in T-ALL.
© 2015  Elsevier  Ltd. All  rights  reserved.. Introduction
NUP98 is a member of the nucleoporin protein family which con-
titutes the nuclear pore complex, the large channel spanning the
uclear envelope to mediate nucleocytoplasmic transport [1]. Since
he NUP98-HOXA9 fusion deriving from recurrent t(7;11)(p15;p15)
as ﬁrst identiﬁed in acute myeloid leukaemia (AML) [2,3], more
han 30 NUP98 partners have been identiﬁed in the myelodysplastic
yndrome (MDS), acute myeloid leukaemia (AML), chronic myeloid
eukaemia in blastic phase (BP-CML), and T-cell acute lymphoblas-
ic leukaemia (T-ALL) [4]. No NUP98 fusions have been detected
n B cell lymphoid malignancies, sofar. The NUP98 amino-terminal
ortion containing FG repeats always participates in fusion proteins
hile the partner gene provides the C-terminal portion. Despite the
eterogeneity, NUP98 partners fall into the two main categories ofPlease cite this article in press as: Crescenzi B, et al. NUP98/11p15 trans
Leuk Res (2015), http://dx.doi.org/10.1016/j.leukres.2015.04.014
omeodomain genes (HD) and non-HD genes. Notably, in mouse
odels HD partners confer oncogenetic properties to a signiﬁcantly
reater extent than non-HD partners [5].
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145-2126/© 2015 Elsevier Ltd. All rights reserved.In T-ALL only 3 partners (SETBP1, CCDC28A, RAP1GDS1)  have
been described to date while 2 others (ADD3 and IQCG) were
reported to be involved in biphenotypic myeloid/T leukaemia. A
speciﬁc fusion such as NUP98/NSD1 is only found in MDS  and AML
[4]. Despite these results the role of fusion partners in determing
disease phenotype is not fully clariﬁed.
To explore this issue we used FICTION (Fluorescent Immunophe-
notype and Interphase Cytogenetic as a Tool for Investigation of
Neoplasms) as a single cell analysis to investigate expression of
myeloid and lymphoid lineage speciﬁcation antigens in leukemic
cells bearing NUP98 translocations.
2. Materials and methods
2.1. Patients
9 patients (5 males, 4 females; age range: 16–65) with 11p15/NUP98 positive
haematological malignancies (2 MDS-RAEB, 5 AML, and 2 T-ALL) were recruited
at the Haematology Departments, Universities of Perugia and Rome (Italy), Centre
for  Human Genetics, University of Leuven (Belgium), and the Department of Clinicallocations affect CD34+ cells in myeloid and T lymphoid leukemias.
Genetics, Erasmus University of Rotterdam (The Netherlands) (Table 1). The identity
of  several fusion partners has already been reported elsewhere [6–11]. All patients
gave their informed consent to sample collection and biological analyses in accor-
dance with the Declaration of Helsinki. The study was approved by the Bioethics
Committee, University of Perugia (Prot.1.X.2011).
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Table 1
Clinical, haematological, cytogenetic and molecolar features of patients with NUP98 translocations.
Cases S/A Diagnosis CD34+ cells◦
(%)
Karyotype NUP98 partner SNPa Mutations
1 M/36 RAEB2 51 46,XY[20] NSD1 normal FLT3-ITD; CEBPA
(c.1004 T>C p.L335P)
2  M/65 RAEB n.a. 46,XY,add(11)(p15)[17]/46,XY[3] NSD1 LOSS: 15q26.1 LOH:
6q24.2-q25.2,
13q12.3-q14.1,
16q11.2-q21,
19p13.1-p13.3
–
3  F/31 AML  86 46,XX[20] NSD1 LOSS: 9p21.2-p21.3 FLT3-ITD
4  M/39 AML-M4 1 30-45,XY,-1[3],-9[4],-
10[4],inv(11)(p15q22)[10],-15[3],-
17[4],-18[4],-19[4],-20[4],-
21[4][cp10]
DDX10 n.a. –
5  M/28 AML-M2 73 46,XY,t(3;11)(q12;p15)[15] LNP1 n.a. FLT3-ITD
6  F/36 AML-M2 1 46,XX,t(11;12)(p15;q13)[15] unknown n.a. –
7  F/60 AML-M0 90 46–47,XX,t(1;17)(q22;q11),t(4;11)
(q1?3;p15),?der(8)(p?)[7],
del(11)(p12p1?3)[6],del(12)
(p11p13),add(14)(q3?2)[7],þ15[3],
del(15)(q1?3q2?2)[cp22]/46,XX[4]
RAP1GDS1 LOSS: 2p25.2, 3q23,
5q13.3-q14.1, 5q22.1,
11p13, 12p11.2-p13.3,
15q11.2-q21.1,
16q12.1, 17q11.2-q12,
19q13.1, 21q21.1
–
8  F/16 T-ALL 0 47,XX,t(4;11)(q21;p15),+8[20] RAP1GDS1 GAIN: 6q23.3,
chromosome 8
NOTCH1
(c.7200 7201ins(GGGAA);
p.N2401Gfs*23
c.7318C>T p.Q2440*
9  M/25 T-ALL 20 46,XY,t(4;11)(q21;p15),del(5)
(q31q35),der(16)t(X;16)
(p11;p13)[12]
RAP1GDS1 LOSS: 5q23.2-q35.3,
16p13.1-p13.3 GAIN:
5p13.3-p15.33, 6q23.3,
Xp21.1-q22.3
NOTCH1
(c.4672G>A,p.G1558R;
c.7403 7408
delinsCCCGCGCAAGGGGC,
p.L2468Pfs*11)
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D, sex; A, age in years; F, female; M,  male; SNPa, sigle nucleotide polymorphism a
ith  excess of blast; AML, acute myeloid leukaemia; T-ALL, T-cell acute lymphobla
dentiﬁed.
.2. Fiction
FICTION was performed as already described [12], using the following mouse
onoclonal antibodies: anti-CD33, CD3, CD7, CD19, CD20, Glycophorin A (Dako,
ilan, Italy), anti-CD34, CD13, CD14 (Becton-Dickinson, Milan, Italy), and anti-
D133 (Miltenyi Biotec S.r.l., Bologna, Italy) antigens and a three-step staining
echnique with Cy3-conjugated polyclonal antibodies. NUP98 gene was investigated
ith two genomic clones (RP11-348A20 and CTD-3234FF16F, both labelled with
pectrum green) encompassing the full gene. Immunophenotype and hybridiza-
ion signals were simultaneously identiﬁed and counted on 10–100 cells for each
ntibody, using an Olympus ﬂuorescence microscope equipped with a double band
lter, a CCD camera (Sensys-Photometrics, Tucson AZ, USA) and image analysis soft-
are (Vysis, SmartCapture, Olympus, Milan, Italy). Two  healthy donors were used
s  normal controls. The cut-off for NUP98 translocation (3 signals) was  established
t the upper limit of normal controls. All slides were evaluated by two independent
bservers. Data are reported as the means of results.
.3. SNP array and Interphase FISH
Single Nucleotide Polymorphism-Array (SNPa) was  performed with CytoScan
D Affymetrix platform, following the manufacturer’s instructions. 250 ng of high
uality genomic DNA obtained from unsorted bone marrow cells of patients nos 1–3
nd 7–9 (Table 1) was  used to study Copy Number Alterations (CNAs) and copy neu-
ral  loss of heterozygosity (cnLOH). Protocol was  supported by Affymetrix GeneChip
ommand Console (AGCC) software. Analysis was performed with Affymetrix
hromosome Analysis Suite 2.0 (ChAS) software. For accurate state detection, ﬁl-
ers were set at 100 kb dimension for CNAs and 10 Mb  dimension for cnLOH.
ur data refer to NetAffx Build 32.3 (hg19) database. Polymorphic copy-number
ariations were excluded from analysis (Database of Genomic variants: http://
rojects.tcag.ca/variation/). Interphase FISH (I-FISH) with fosmids G248P89100B2,
ncompassing MYB, and G248P89828A1, ﬂanking the 3′MYB, was done in
ase no. 9.
.4. Mutational analysisPlease cite this article in press as: Crescenzi B, et al. NUP98/11p15 trans
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Mutational analysis was  performed on DNA obtained from patients’ unsorted
one marrow cells. The CEBPA, TP53, and TET2 whole coding sequences were ana-
yzed by DHPLC. NOTCH1 (exons 26,27,34), FLT3 (ITD and D835Y), PU.1 (exon 3),
ETBP1 (exon 4), GATA1 (exon 2), GATA2 (exons 3,4,5,6,7), GATA3 (exons 4,5,6), and
NMT3A (exons 15,19,20,21,22,23) were investigated by Sanger sequencing.RAEB2, refractory anaemia with excess of blast, type 2; RAEB, refractory anaemia
ukaemia;◦ by cytometry at diagnosis; n.a., not available; – no additional mutations
3. Results
3.1. Fiction
FICTION results are summarized in Table 2. Representative
images of FICTION experiments in patient no.1 are showed in Fig. 1.
In MDS  and AML  (patients nos. 1–7), NUP98+ cells were expressed
in the myelomonocytes (range: 60–94% for CD33+; 31–100% for
CD13+, 60–90% for CD14+), the erythroid lineage (33–100% for Glyc
A+), B- cells (39–69% for CD20+; 35–74% for CD19+) and T cells
(13–76% for CD7+; 42–70% for CD3+).
In T-ALL (patients nos. 8 and 9) only T cells were involved
(83–90% CD7+ and 100% CD3+) downstream to CD34+/CD133+
hematopoietic precursors.
3.2. SNP array and I-FISH
A total of 24 events were detected in 6/9 patients, 20 CNVs
(5 gains; 15 losses) and 4 cnLOHs. Both patients with NUP98+
T-ALL (cases nos. 8 and 9, Table 1) presented a small gain at chro-
mosome 6q23.3, corresponding to MYB  gene duplication. In case
no. 9, I-FISH detected MYB  tandem duplication in about 50% of
nuclei.
3.3. Mutational analysis
NOTCH1 mutations were found only in T-ALL cases (cases nos.
8 and 9). In patient no. 8 we observed c.7200 7201ins(GGGAA)
p.N2401Gfs*23 and the recurrent c.7318C>T p.Q2440*, both in
the PEST domain. In patient no. 9 we  detected c.4672G>A,locations affect CD34+ cells in myeloid and T lymphoid leukemias.
p.G1558R (HD domain) and c.7403 7408delinsCCCGCGCAAGGGGC,
p.L2468Pfs*11 (PEST domain) (Table 1). CEBPA analysis showed
patient no. 1 (RAEB2) carried a novel heterozygous missense C-
terminal mutation c.1004T>C p.L335P (Table 1). FLT3-ITD was  found
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Table  2
FICTION results.
case 1 case 2 case 3 case 4 case 5 case 6 case 7 case 8 case 9 control 1 control 2
CD34 92/99 (93) 13/36 (36) 86/100 (86) 34/47 (72) 57/92 (62) 9/13 (69) 32/40 (80) 14/15 (93) 50/53 (94) 2/50 (4) 0/50 (0)
CD133 40/51 (78) 18/31 (58) – 20/30 (67) 40/53 (75) – 22/26 (85) 20/30 (67) – 0/54 (0) 1/42 (2)
CD33  94/100 (94) 50/83 (60) 50/53 (94) 55/72 (76) 28/30 (93) – 60/100 (60) 1/25 (4) – 2/60 (3) 2/56 (4)
CD13  90/100 (90) 70/100 (70) 85/110 (77) 50/83 (60) 41/62 (66) – 24/78 (31) 2/52 (4) 0/20 (0) 0/40 (0) 2/52 (4)
CD14  36/49 (74) 60/100 (60) – 70/78 (90) 60/90 (67) – 20/30 (67) 0/31 (0) – 0/52 (0) 0/50 (0)
Glycophorin A 90/106 (85) 70/93 (75) 0/40 (0) 31/40 (78) 10/10 (100) – 23/70 (33) 2/39 (5) 0/16 (0) 0/55 (0) 4/85 (5)
CD3  0/100 (0) 70/100 (70) 0/34 (0) 22/53 (41) 0/22 (0) 0/50 (0) 13/29 (45) 38/38 (100) 100/100 (100) 0/60 (0) 0/63 (0)
CD7  15/110 (13) 60/100 (60) 0/80 (0) 23/30 (76) 1/45 (2) 0/52 (0) 40/80 (50) 50/60 (83) 100/110 (90) 1/52 (2) 0/70 (0)
CD20  0/100 (0) 50/100 (50) – 34/49 (69) 1/25 (4) 
CD19  0/100 (0) 40/100 (40) – 57/77 (74) 0/46 (0) 
Case number refers to Table 1. Number of positive/total cells (percentage); –, not done.
Fig. 1. FICTION (Fluorescence Immunophenotype and Interphase Cytogenetics as a
Tool for Investigation of Neoplasms) on intact cells in MDS  with NUP98 transloca-
tion (patient no. 1). FICTION with monoclonal antibodies against CD34, CD33, CD13,
Glycophorin A, CD19, CD3 (red). Red staining detects positive intact cells express-
ing  the speciﬁc antigen. Green spots indicate FISH signals in the nuclei using a FITC
labelled genomic probe for NUP98. Two  green signals indicate normal disomic cells;
t
p
w
i
(
S
4
chree show NUP98 split because of translocation (magniﬁcation 1.000×). (For inter-
retation of the references to color in this ﬁgure legend, the reader is referred to the
eb  version of this article.)
n three cases, two with NUP98-NSD1 and one with NUP98-LNP1
Table 1). No mutations were detected in the TP53, TET2, PU.1,
ETBP1, GATA1,  GATA2,  GATA3,  and DNMT3A genes (data not shown).Please cite this article in press as: Crescenzi B, et al. NUP98/11p15 trans
Leuk Res (2015), http://dx.doi.org/10.1016/j.leukres.2015.04.014
. Discussion
The present study was designed to gain insights into clonal
ells that are affected by NUP98 leukemic translocations and to– 22/36 (39) 1/30 (3) 0/30 (0) 0/35 (0) 2/50 (4)
– 8/23 (35) 1/24 (4) – 2/44 (5) 0/36 (0)
investigate whether NUP98 partners play a role in the leukemic
phenotype. FICTION, the technique we  used, was  previously
validated as a reliable qualitative single cell analysis for charac-
terizing the leukemic bulk in genetic entities [12–15]. It combined
immunostaining with monoclonal antibodies against lineage spec-
iﬁcation antigens with in situ hybridization of DNA probes to detect
genomic lesions in our 9 representative cases (7 MDS/AML and 2
T-ALL) of NUP98 positive malignancies affecting myeloid and T-cell
leukemias.
Studying four NUP98 translocations with partners NSD1, DDX10,
LNP1, and RAP1GDS1 we showed that all NUP98 translocations
were present in CD34+/CD133+ hematopoietic precursors in both
MDS/AML and T-ALL, even when cases displayed no evidence of
CD34 expression at diagnostic cytometry (Table 1, cases nos. 4, 6,8).
Interestingly, a CD34+ multi-potent progenitor was reported to be
involved in well established cytogenetic-molecular MDS/AML sub-
types, such as those bearing PML-RARA, RUNX1-ETO, inv(3), 5q-, +8
and monosomy 7 [16–21]. As far as we know present results are
the ﬁrst observation of a speciﬁc genetic lesion in the CD34+ cells
of T-ALL.
The present investigation found the CD34+/CD133+ precursors
that were affected by a NUP98 translocation were restricted to dif-
ferent lineages in MDS/AML and in T-ALL. In fact, only CD3+ CD7+
cells were involved in T-ALL while, despite inter-individual varia-
tions, myelomonocytic, erythroid, B and T lineages were involved in
MDS/AML (Table 2 and Fig. 1). Interestingly one case of AML  (no. 7)
and one case of T-ALL (no. 8), showed the RAP1GDS1 NUP98 partner
with the same exon2 fusion point [10,11], suggesting the leukaemia
phenotype could have been addressed by additional (epi)genetic or
microenvironmental events.
In the search for additional events we performed SNPa and
mutational analysis on 11 candidate genes in our series. We  found
6q23.3/MYB tandem duplication and NOTCH1 gain-of-function
mutations in T-ALL (Table 1, cases nos. 8 and 9). MYB deregula-
tion is recognized as a leukemogenic event in a T-ALL subgroup
with MYB/6q23.3 tandem duplication/gain or translocation with
the TCR gene [22]. NOTCH1 activation initiates the T-cell differenti-
ation programme of uncommitted precursors in the thymic stroma
[23] and NOTCH1 mutations are an established oncogenic event in
T-ALL [24]. As expected, NOTCH1 mutations were not found in our
cases of MDS/AML.
In MDS/AML we identiﬁed FLT3-ITD (Table 1, cases nos. 1, 3 and
5) and a mono-allelic CEBPA mutation, involving the C-terminal
DNA binding domain (Table 1, case no. 1). The myeloid effects of
FLT3 and CEBPA mutations were proven in in vivo models. FLT3-
ITD induced myeloid progenitor expansion in mice [25] and strong
synergism between NUP98-NSD1 fusion and FLT3-ITD increased
proliferation and promoted self-renewal with short latency tolocations affect CD34+ cells in myeloid and T lymphoid leukemias.
AML development [26]. Moreover Kato et al. [27], using a BMT
(Bone Marrow Transplantation) model, provided evidence for the
oncogenic properties of a C-terminal CEBPA mutation and for its
collaboration with FLT3-ITD in AML  induction.
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Fig. 2. Proposed schematic representation for T-ALL and AML  bearing NUP98
translocations. NUP98 affects CD34 precursors. An additional genetic change like
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ypothetical additional events that remain to be discovered.
Our results are schematically represented in Fig. 2 suggesting
hat additional mutations contributed to the phenotypic expression
f NUP98 rearranged leukemias.
. Conclusions
This ex vivo study provided evidence that NUP98 translocations
re early leukemic lesions which affect a CD34+ precursor. Myeloid
r T-lymphoid leukemic immunophenotypes were not addressed
y RAP1GDS1 gene as translocation partner. New insights into
dditional lineage speciﬁc genetic events associated with NUP98
ranslocation in both T-ALL and MDS/AML were provided.
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